You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黄医药:未有具体再上市计划 关注香港及上海市场情况
阿思达克 03-17 12:41
长和(00001.HK)有份投资的和黄医药(HCM.US)首席财务官郑泽锋在全年业绩网上会议表示,近期市场对公司再上市计划有不同报道,但公司目前仍在探讨上市机会,未有具体计划,会持续关注香港及上海等其他证券市场的情况。

首席执行官贺隽补充指,过去一年多上海科创板有良好发展,香港容许未录盈利生物科技商上市後,亦提供很多渠道及融资机会,会继续关注不同市场,强调公司未有在港上市的具体计划及时间表。

公司去年亏损扩大至逾1.25亿美元,贺隽称公司有很多全球性研发正在进行,预料研发开支今年会进一步增至约3亿美元。不过随着多种药物陆续商业化,包括已於中国开始销售的「爱优特」和「苏泰达」,及料将於年中获批上市的「赛沃替尼」,估计公司今年收入已可大幅增长达四倍,到1.1亿至1.3亿美元,有助抵销研发支出。在未来收入料可显着提升下,预期公司於2024年至2025年可非常接近收支平衡。

另外,郑泽锋提到,未来五年公司将投入1.3亿美元兴建位於上海的新生产厂房,建成後产能料可达现时苏州厂房的五倍,有望满足额外的全球生产需求。而公司手头现金充裕,足以应付未来两年以上的营运,公司亦会继续评估出售非处方药等非核心资产的机会。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account